目 录 | | | | 二、财务报表……………………………………………………… 第 | 6—12 | | 页 | | --- | --- | --- | --- | | （一）资产负债表………………………………………………第 | 6—7 | | 页 | | （二）利润表……………………………………………………… | 第 | 8 | 页 | | （三）现金流量表………………………………………………… | 第 | 9 | 页 | | （四）所有者权益变动表……………………………………第 | 10—12 | | 页 | | | | 审 计 报 告 天健审〔2025〕6973 号 山东博苑医药化学股份有限公司全体股东： 一、审计意见 我们审计了山东博苑医药化学股份有限公司（以下简称博苑股份公司）财务 报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及 母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表，以 及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了博苑股份公司2024年12月31日的合并及母公司财务状况 ...

中泰证券股份有限公司 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部 控制评价结果推测未来内部控制的有效性具有一定的风险。 二、内部控制评价结论 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准 日，不存在财务报告内部控制重大缺陷，董事会认为，公司已按照企业内部控制 规范体系和相关规定的要求在所有重大方面保持了有效的财务报告内部控制。 根据公司非财务报告内部控制重大缺陷认定情况 ...

目 录 一、内部控制审计报告…………………………………………第 1—2 页 1 内部控制审计报告 天健审〔2025〕6974 号 山东博苑医药化学股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了山东博苑医药化学股份有限公司（以下简称博苑股份公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 第 1 页 共 2 页 我们认为，博苑股份公司于 2024 年 12 月 31 日按照《企业内部控制基本规 范》和相关规定在所有重大方面保持了有效的财务报告内部控制。 天健会计师事务所（特殊普通合伙） 中国注册会计师： 一、企业对内部控制的责任 按照《企 ...

一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 中泰证券股份有限公司 关于山东博苑医药化学股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中泰证券股份有限公司（以下简称"中泰证券"或"保荐人"）作为山东博苑医 药化学股份有限公司（以下简称"博苑股份"、"公司"）首次公开发行股票并在创 业板上市的保荐人履行持续督导职责，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》等有关规定，对博苑股份 2024 年度募集资 金存放与使用情况进行了核查，核查意见如下： 经中国证券监督管理委员会《关于同意山东博苑医药化学股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1415 号）同意注册，博苑股份首 次公开发行人民币普通股（A 股）股票 2,570.00 万股，每股面值 1 元，每股发行 价格为人民币 27.76 元。本次发行募集资金总额为 71,343.20 万元，扣除发行费 用 8,526.43 万元（不含税 ...

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告………………第 3—9 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕6976 号 山东博苑医药化学股份有限公司全体股东： 我们鉴证了后附的山东博苑医药化学股份有限公司（以下简称博苑股份公司） 管理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供博苑股份公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为博苑股份公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 博苑股份公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》（证监会公告〔2022〕15 号）和《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕 1146 号）的规定编制《关于募集资金年度存放与使用情况的专项报告》，并保证 其内容 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,327,877,895.31, representing a 29.53% increase compared to ¥1,025,151,572.87 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥213,125,786.64, up 17.04% from ¥182,101,838.29 in 2023[18]. - The company's total assets increased by 82.99% to ¥1,872,000,814.89 at the end of 2024, compared to ¥1,023,010,879.53 at the end of 2023[18]. - The basic earnings per share for 2024 was ¥2.76, a 16.95% increase from ¥2.36 in 2023[18]. - The company's operating cost reached CNY 998,800,658.23, up 35.12% compared to the previous year, resulting in a gross profit margin of 24.78%, a decrease of 3.11 percentage points[50]. - The company's iodine products accounted for 71.78% of total revenue, generating CNY 953,092,133.25, with a year-on-year growth of 19.00%[47]. - The trade business segment saw significant growth, with revenue increasing by 155.41% to CNY 145,928,265.50[47]. Research and Development - The company is committed to enhancing its research and development capabilities to drive innovation in new products[12]. - The company has 11 invention patents and 8 utility model patents related to iodide production, enhancing product quality and recovery rates[35]. - The company has a strong focus on R&D, continuously investing in new technologies and products to meet market demands[32]. - Research and development expenses amounted to CNY 4,133.70 million, reflecting a 15.90% increase from the previous year, indicating a continued commitment to innovation[44]. - The company’s R&D investment amounted to approximately ¥41.34 million in 2024, representing 3.11% of operating revenue[63]. - The number of R&D personnel increased by 26.03% to 92 in 2024 from 73 in 2023[63]. Market Expansion and Strategy - The company is exploring market expansion opportunities, particularly in the field of fine chemicals and pharmaceuticals[12]. - The company is focused on expanding its market presence in the fine chemical sector, supported by national policies promoting green and low-carbon development[29]. - The company has outlined strategic plans for potential mergers and acquisitions to strengthen its market position[12]. - The company aims to strengthen its market position in fine chemicals while promoting a dual circulation development model that integrates domestic and international markets[83]. - The company is actively pursuing strategic partnerships and potential acquisitions to enhance its competitive position[122]. Environmental and Social Responsibility - The company has a clear focus on environmental and social responsibility as part of its operational strategy[12]. - The company emphasizes compliance and has obtained various safety and environmental permits, including a safety production license valid until January 27, 2025[38]. - The company has established a waste incineration facility and rotary kiln for the treatment of organic waste liquids and other hazardous materials[164]. - The company has implemented measures for carbon emission reduction, including the use of MVR evaporators and waste heat boilers, achieving 100% usage of energy-saving lights in the factory[168]. - The company conducts self-monitoring of emissions and wastewater discharge, ensuring 100% reporting of monitoring data to regulatory platforms[166]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation of the board and shareholder meetings[99][100]. - The company has a clear organizational structure to improve operational efficiency and drive sustainable growth[92]. - The company has established a comprehensive corporate governance structure involving the shareholders' meeting, board of directors, supervisory board, and management team to ensure effective internal control systems[154]. - The current board includes independent directors with diverse backgrounds, enhancing governance and oversight[119]. - The company has a complete decision-making process for profit distribution, ensuring the protection of shareholders' rights[146]. Shareholder Engagement and Financial Independence - The company emphasizes the protection of investor rights, providing diverse communication channels and enhancing the transparency of information disclosure[170]. - The company has no shared bank accounts with its controlling shareholders or actual controllers, ensuring financial independence[107]. - The company has established a commitment to maintain compliance with relevant legal and regulatory requirements, ensuring accountability for any breaches[178]. - The company will not engage in any business that competes directly or indirectly with the issuer and its subsidiaries[192]. - The company will not occupy the issuer's funds through loans or other means, nor will it require the issuer to provide guarantees[195]. Talent Development and Employee Management - The company has established a talent development framework focusing on internal training, including safety governance and organizational development training[144]. - The total number of employees at the end of the reporting period is 667, with 746 employees receiving salaries during the period[141]. - The company implements a salary system based on job standards, linking it closely with job evaluation and performance management[142]. - A specialized training institution, "Future Academy," has been established to enhance innovation and employee safety awareness[143]. - The company has a comprehensive incentive mechanism for key positions and outstanding contributors, including performance evaluation and stock options[142]. Financial Strategy and Cash Management - The company plans to distribute cash dividends of RMB 3 per 10 shares, totaling RMB 30,840,000 (including tax) based on a total share capital of 102,800,000 shares[145]. - The cash dividend distribution accounts for 100% of the distributable profit, which amounts to RMB 631,838,780.80[148]. - The company has approved the proposal for the use of idle raised funds for cash management, reflecting financial strategy adjustments[139]. - The company will not issue bonus shares and will not increase capital from the capital reserve in the current distribution plan[145]. - The company has committed to maintaining timely payments to suppliers, ensuring a solid foundation for long-term stable partnerships[172].

Financial Performance - The company's revenue for Q1 2025 was CNY 320,236,400.36, representing a 4.02% increase compared to CNY 307,869,020.61 in the same period last year[5]. - Net profit attributable to shareholders decreased by 4.05% to CNY 49,077,469.40 from CNY 51,246,353.26 year-on-year[5]. - Basic earnings per share fell by 28.04% to CNY 0.4774 from CNY 0.6647 in the previous year[5]. - Total operating revenue for the current period reached ¥320,236,400.36, an increase of 4.45% compared to ¥307,869,020.61 in the previous period[21]. - Net profit for the current period was ¥49,077,469.40, a decrease of 4.19% from ¥51,147,841.95 in the previous period[23]. - Basic and diluted earnings per share were both ¥0.4774, down from ¥0.6634 in the prior period[23]. Cash Flow and Liquidity - Operating cash flow turned negative at CNY -35,360,274.62, a decline of 152.92% compared to CNY 66,820,656.13 in the same period last year[5]. - The net cash flow from operating activities was -35,360,274.62, a decrease from 66,820,656.13 in the previous period[26]. - The company reported a total cash inflow from operating activities of 353,011,730.38, up from 299,260,780.74 in the previous period[26]. - The company's cash and cash equivalents decreased by 58.12% to CNY 401,423,116.62 from CNY 958,580,504.06 at the beginning of the period[8]. - The net increase in cash and cash equivalents was -547,189,456.83, contrasting with an increase of 46,286,625.94 in the previous period[27]. - The ending balance of cash and cash equivalents was 378,164,361.04, down from 240,323,404.67 in the previous period[27]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,872,609,043.20, a slight decrease of 0.60% from CNY 1,872,000,814.89 at the end of the previous year[5]. - The total current assets amount to 1,357,546,153.27 RMB, a slight decrease from 1,378,699,714.08 RMB in the previous period[18]. - The total liabilities decreased from ¥227,165,672.67 to ¥210,101,755.80, indicating improved financial health[22]. - The total equity attributable to shareholders rose slightly to ¥1,662,507,287.40 from ¥1,656,652,466.88, showing stability in ownership value[22]. Research and Development - Research and development expenses increased by 89.99% to CNY 13,656,163.10 from CNY 7,187,843.05 year-on-year, indicating a significant boost in R&D investment[10]. - Research and development expenses increased significantly to ¥13,656,163.10, up from ¥7,187,843.05, reflecting a focus on innovation[22]. Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 18,723[15]. - The largest shareholder, Li Chenglin, holds 30.40% of the shares, totaling 31,250,000 shares[15]. - The second-largest shareholder, Yu Guoqing, holds 26.51% of the shares, totaling 27,250,000 shares[15]. Inventory and Receivables - The total inventory is valued at 253,366,315.46 RMB, up from 210,394,935.08 RMB in the previous period[18]. - The total accounts receivable is 139,152,690.80 RMB, an increase from 120,781,153.93 RMB in the previous period[18]. - The accounts receivable financing dropped by 67.10% to CNY 8,822,349.19, primarily due to a reduction in high-credit-rated receivables[8]. Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 930.92% to CNY 41,377,392.76, attributed to an increase in advance payments received[8]. - The company experienced a 76,885.85% decline in net cash flow from financing activities, primarily due to cash dividends paid during the reporting period[13]. - Total operating costs amounted to ¥265,344,140.70, up 6.77% from ¥248,480,830.77 in the prior period[22]. - The company reported a decrease in tax expenses to ¥6,391,553.22 from ¥7,927,419.43, which may positively impact net income[22]. Strategic Initiatives - The company has not disclosed any new product developments or market expansion strategies in the provided content[16]. - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[23]. Audit Information - The company did not conduct an audit for the first quarter report[28].

2025 年第二次临时股东会的 法律意见书 国枫律股字[2025]A0105 号 致：山东博苑医药化学股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年第二次临时股东会（以下简称"本次会议"）。 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于山东博苑医药化学股份有限公司 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《山东博苑医药化学 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-012 山东博苑医药化学股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无变更、否决提案的情形； 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间：2025 年 4 月 7 日（星期一）下午 15：00 2、会议召开形式：采取现场投票和网络投票相结合的方式 3、会议召开地点：山东省寿光市侯镇海洋化工园区新海路与大九路路口北 200 米山东博苑医药化学股份有限公司会议室 4、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 4 月 7 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为：2025 年 4 月 7 日 9:15—15:00 期间的任意时间。 5、会议召集人：公司第二届董事会 6、会议主持人：公司董事长李成林先生 7、本次会议的召集、召开符 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-008 山东博苑医药化学股份有限公司 第二届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东博苑医药化学股份有限公司（以下简称"公司"）第二届董事会第八次会 议于 2025 年 3 月 16 日以邮件等方式发出通知，会议于 2025 年 3 月 21 日在公司 会议室以现场结合通讯表决的方式召开。会议应参加表决董事 7 人，实际参加表 决董事 7 人（其中于国清先生、袁瑞先生、高磊先生、张志红女士、吕志果先生 通过通讯方式参加会议）。会议由董事长李成林先生召集并主持，公司监事及高 级管理人员列席了会议。本次会议的召集、召开和表决程序符合法律、法规及《公 司章程》的规定。 本议案尚需提交股东会以特别决议方式审议。 2、审议通过《关于召开 2025 年第二次临时股东会的议案》 公司定于 2025 年 4 月 7 日（星期一）下午 15：00 在山东省寿光市侯镇海洋 化工园区新海路与大九路路口北 200 米山东博苑医药化学股份有限公司会议室 采取现场 ...